WebApr 11, 2024 · Cisplatin-resistant mRNA and miRNA models were constructed by Logistic regression, classification and regression tree and C4.5 decision tree classification algorithm with previous feature selection performed via least absolute shrinkage and selection operator (LASSO). qRT-PCR and western-blotting of A549 and H358 cells, as well as … WebFeb 28, 2024 · Complexes 36–40 were tested against lung carcinomas A549 and A549/DDP, cisplatin-insensitive cells, and normal healthy (HL-7702) cells. ... (IC50 = 3.87 μM), complex 40 (IC 50 = 0.91 μM), and cisplatin (IC 50 = 50.12 μM), all of which showed lower cytotoxic effects against HL-7702 compared with the standard approved regimen …
Inhibitory concentrations 50 (IC50) and CI95 for cisplatin and …
WebMar 22, 2024 · a A549 and A549/DDP cells were exposed to different concentrations of cisplatin (1, 10, 20, 40, 80, 160 μM) for 48 h, followed by the determination of cell … WebA cisplatin-resistant cell subline, HeLa/CDDP cells, showed a 19-fold resistance to cisplatin compared with the parent cells. The subline showed a collateral sensitivity to paclitaxel. An equitoxic dose (IC50) of cisplatin produced DNA fragmentation in HeLa cells but not in HeLa/CDDP cells. sickness worksheet pdf
The effect of acquired cisplatin resistance on sensitivity to …
WebThe median inhibitory concentration (IC50 ) in cisplatin-treated A549 and A549/DDP cells was 5.769 ± 0.24 μmol/L and 28.373 ± 0.96 μmol/L, respectively; the cisplatin resistance of A549 cells was about five times that of A549/DDP cells. WebInhibitory concentrations 50 (IC50) and CI95 for cisplatin and compound 12 in HCT116 and A549 cells. Source publication +12 Virtual Screening and Biological Evaluation of Inhibitors Targeting... WebAug 7, 2024 · Thus, the IC50 of curcumin against A549/DDP and H1299/DDP cells was 10 μ g/mL. In addition, the maximum nonlethal concentration of curcumin against A549/DDP and H1299/DDP cells was 2.5 μ g/mL. These results showed that curcumin can significantly decrease cell viability of drug-resistant NSCLC cells. (a) (b) (c) (d) Figure 1 sickness words